UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 18, 2005
MannKind Corporation
| Delaware (State or other jurisdiction of incorporation or organization) |
000-50865 (Commission File Number) |
13-3607736 (IRS Employer Identification No.) |
| 28903 North Avenue Paine Valencia, California (Address of principal executive offices) |
91355 (Zip Code) |
Registrant’s telephone number, including area code: (661) 775-5300
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||
| o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||
| o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||
| o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CRF 240.13e-4(c)) | ||||
1.
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
(d) The Registrant’s Board of Directors elected Henry L. Nordhoff as a director effective March 18, 2005. Mr. Nordhoff was also named to the Compensation Committee of the Registrant’s Board of Directors. The Registrant is not aware of any transaction requiring disclosure under Item 404(a) of Regulation S-K.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits. The following exhibit is filed herewith:
| Number | Description | |
99.1
|
Press release of MannKind Corporation, dated March 18, 2005. |
2.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MANNKIND CORPORATION |
||||
| By: | /s/ Richard L. Anderson | |||
| Name: | Richard L. Anderson | |||
| Dated: March 18, 2005 | Title: | Chief Financial Officer | ||
3.
EXHIBIT INDEX
| Number | Description | |
99.1
|
Press release of MannKind Corporation, dated March 18, 2005. |
4.
Exhibit 99.1
HENRY L. NORDHOFF JOINS BOARD OF DIRECTORS OF MANNKIND CORPORATION
VALENCIA, Calif. (March 18, 2005) – MannKind Corporation (Nasdaq NM: MNKD) today announced that Henry L. Nordhoff has been appointed to the board of directors of MannKind Corporation and to the board’s Compensation Committee. Mr. Nordhoff’s addition brings the board of directors to a total of nine members.
“Hank’s extensive industry experience and insights will serve us very well as we continue the development activities of MannKind,” said Alfred E. Mann, MannKind’s CEO and Chairman. “We will also benefit from Hank’s extensive network as we evolve our technologies and assess new strategic opportunities for our company.”
Since July 1994, Henry Nordhoff has served as President and Chief Executive Officer of Gen-Probe Incorporated. Prior to that, he was President and Chief Executive Officer of TargeTech, Inc., a gene therapy company that was merged into the Immune Response Corporation. Most of Mr. Nordhoff’s earlier career was spent at Pfizer, Inc. in senior positions in Brussels, Seoul, Tokyo and New York. He received a B.A. in international relations and political economy from Johns Hopkins University and an M.B.A. from Columbia University.
About MannKind Corporation
MannKind focuses on the discovery, development and commercialization of therapeutic products for
diseases such as diabetes and cancer. The Company recently commenced Phase 3 clinical trials in
Europe of its lead product, the Technosphere® Insulin System, to study its potential for
the treatment of diabetes. This System consists of a proprietary dry powder
Technosphere® formulation of insulin that is inhaled into the deep lung using the
Company’s MedTone™ inhaler. MannKind believes that the performance characteristics, unique
kinetics, convenience and ease of use of the Technosphere® Insulin System may have the
potential to change the way diabetes is treated. For more information on MannKind Corporation and
its technology, visit www.mannkindcorp.com.